EGFR and colorectal carcinoma: According to the consensus molecular subtypes of classification for CRC (CMS classification), the CMS4 group, defined as a subtype of CRC with increased CAF component and mesenchymal activation, features higher resistance to chemotherapy and anti-EGFR therapy and has the worst prognosis (25).